Osimertinib
Refractory Multiple Myeloma
National Cancer Institute (NCI)Small moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
18 Active assets in the Refractory Multiple Myeloma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Sorafenib OHSU Knight Cancer Institute | Phase 2 | BB |
Flavopiridol National Cancer Institute (NCI) | Phase 2 | BB |
2-methoxyestradiol National Cancer Institute (NCI) | Phase 2 | BB |
Tas-102 National Cancer Institute (NCI) | Phase 2 | B |
su011248 OHSU Knight Cancer Institute | Phase 2 | B |
View all 35 →
Same molecule, other indications
Osimertinib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →